This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
See Cramer's multi-million dollar portfolio for FREE and get his new book Get Rich Carefully! Learn More

Hagens Berman Continues Abiomed Investigation Into Possible Securities Law Violations On Behalf Of Investors

Hagens Berman, an investor-rights law firm, is continuing to investigate Abiomed Inc. (NASDAQ:ABMD) regarding possible securities law violations following the company’s disclosure of a Department of Justice (DOJ) probe into the marketing and labeling of its flagship product, the Impella 2.5 system.

Hagens Berman is investigating potential claims under the securities laws that could affect investors who purchased Abiomed common stock after November 3, 2011, and before the company disclosed the probe on November 1, 2012.

Investors who purchased or otherwise acquired Abiomed stock prior to the company’s disclosure are encouraged to contact Hagens Berman to discuss legal representation. Investors can contact Hagens Berman Partner Reed R. Kathrein, who is leading the firm’s investigation, by calling (510) 725-3000 or by emailing ABMD@Hbsslaw.com.

Following the disclosure of the DOJ probe, Abiomed stock fell more than 30 percent on Nov. 1, 2012. The stock continues to trade more than 25 percent below its Oct. 31, 2012 high of nearly $20.00.

The firm’s investigation of Abiomed centers around the company’s Impella 2.5 system, which is used to improve blood flow in heart surgery patients. The company has disclosed a DOJ investigation into marketing of the product. The Food and Drug Administration sent a letter to Abiomed in June 2011, accusing the company of making “objectionable” claims about an Impella system and requesting that the company immediately stop marketing for uses not approved by the FDA. In November 2011, the company told analysts that the issues in the warning letter were resolved.

“We agree with analysts that the DOJ’s probe had a serious adverse impact on Abiomed’s stock price,” said Mr. Kathrein. “We are trying to determine if the company is marketing its Impella system outside the bounds of the officially-sanctioned uses authorized by the Food and Drug Administration, and therefore, if investors may have a legal claim against the company.”

Stock quotes in this article: ABMD 

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 +2.54 0.14%
NASDAQ 4,095.5160 +9.2910 0.23%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs